<DOC>
	<DOCNO>NCT00256204</DOCNO>
	<brief_summary>A 2 phase study evaluate disease progression Parkinson 's disease patient take rasagiline</brief_summary>
	<brief_title>A Randomized Placebo Controlled Study Show That Rasagiline May Slow Disease Progression Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Men woman idiopathic PD whose diagnosis confirm screening , least two cardinal sign without know suspected cause parkinsonism . If tremor present , subject must unilateral onset persistent asymmetry . Subjects diagnosis early idiopathic PD le 1½ year duration time document diagnosis . Subjects whose clinical condition time enrollment require antiPD treatment require next 9 month . Willing able give inform consent . Subjects young 30 old 80 year . Subjects loss postural reflex . Subjects UPDRS Tremor score 3 great limb . Subjects Hoehn &amp; Yahr Stage III great screening . Subjects freeze walking . Subjects follow feature tend exclude PD cause Parkinsonism : History repeat stroke stepwise progression Parkinsonian feature History repeat head injury history definite encephalitis Sustained remission Supranuclear gaze palsy Cerebellar sign Early severe autonomic involvement Babinski 's sign Presence cerebral tumour communicate hydrocephalus MPTP exposure Oculogyric crises Subjects previous use rasagiline selegiline Subjects use antiPD medication basis time prior baseline Subjects use antiPD medication ( include anticholinergic ) less 3 week 3 month period prior baseline . ( include single LDopa dose part LDopa test ) Subjects use antiPD medication ( include anticholinergic ) less 3 week prior 3 month period precede baseline whose antiPD medication intentionally cease order subject enter study . Subjects clinically significant unstable medical surgical condition may preclude safe complete participation Hypertensive subject whose BP well control accord medical record observe week home BP record prior baseline Subjects diagnose melanoma base screen dermatologic examination , history melanoma . Subjects suspicious lesion baseline undergo biopsy Subjects significant cognitive impairment define MMSE score &lt; 26 Subjects clinically significant psychiatric illness , include major depression [ Beck Depression Inventory ( short form ) ≥15 Subjects history alcohol substance abuse within past 2 year Subjects take experimental medication within 60 day prior baseline Subjects use coenzyme Q10 ( daily dose &gt; 300 mg ) within 120 day prior baseline Subjects use sympathomimetics ( include overthecounter remedy nasal oral ) , dextromethorphan , pethidine St. John 's Wort within 7 day prior baseline Subjects use antidepressant within 42 day prior baseline Subjects use ciprofloxacin , potent CYP 1A2 inhibitor within 7 day prior baseline Subjects use MAO inhibitor include reserpine methyldopa within three month prior baseline , treatment antiemetic antipsychotic medication central dopamine antagonist activity within six month prior baseline Women postmenopausal , surgically sterilize , use adequate birth control [ oral birth control pill , IUD , long act injectable form contraception ; barrier method alone ( i.e. , condom ) sufficient ] . Women childbearing potential without negative pregnancy test screening . Nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Parkinson 's</keyword>
	<keyword>Rasagiline Mesylate</keyword>
</DOC>